Global Plasma-derived Therapies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Description

Plasma-derived Therapies: These are medicinal products that are manufactured from human plasma, the liquid component of blood. Plasma contains important proteins, clotting factors, and antibodies that can be processed and concentrated to create products used in various medical treatments. PDPs are essential for treating conditions such as hemophilia, immune deficiencies, and certain autoimmune diseases.

According to our (Global Info Research) latest study, the global Plasma-derived Therapies market size was valued at US$ 33650 million in 2023 and is forecast to a readjusted size of USD 55550 million by 2030 with a CAGR of 7.3% during review period.

Driver of the Plasma-derived Therapies Market:
One of the main drivers of the plasma-derived therapies market is the increasing prevalence of rare and chronic diseases, such as hemophilia, primary immunodeficiency disorders, and autoimmune diseases. These conditions require ongoing treatment with plasma-derived products like clotting factors, immunoglobulins, and albumin. The growing awareness and diagnosis rates of such diseases, along with advancements in plasma collection and fractionation technologies, have contributed to a higher demand for these therapies. Additionally, increasing investments in healthcare infrastructure and government support in emerging markets are fueling market growth.

Challenge of the Plasma-derived Therapies Market:
A key challenge in this market is the complex and costly process of plasma collection and product manufacturing. Plasma-derived therapies require large volumes of plasma, which can only be obtained through human donors. The stringent regulations surrounding plasma collection, donor screening, and testing to ensure safety make the process time-consuming and expensive. Furthermore, any disruption in plasma supply chains, such as those caused by geopolitical issues or pandemics, can lead to shortages and impact treatment availability.

The outbreak of COVID-19 pandemic has led to decrease in number of blood donations and plasma collections, which hampers the market growth as it leads to shortage in raw material supply.

The classification of Plasma-derived Therapies includes Immune Globulin, Coagulation Factor, Albumin and Other. In 2023, Immune Globulin accounted for a share of 51% in the global Plasma-derived Therapies market.

North America is the largest consumption place, with a revenue market share nearly 40% in 2023. Following North America, Europe is the second largest consumption place with the revenue market share of 24 %; China is also an important sales region for the Plasma-derived Therapies.

This report is a detailed and comprehensive analysis for global Plasma-derived Therapies market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Plasma-derived Therapies market size and forecasts, in consumption value ($ Million), 2019-2030
Global Plasma-derived Therapies market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Plasma-derived Therapies market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Plasma-derived Therapies market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Plasma-derived Therapies
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Plasma-derived Therapies market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation
Plasma-derived Therapies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation
Plasma-derived Therapies market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Immune Globulin
    Coagulation Factor
    Albumin
    Other

Market segment by Application
    Hospital
    Retail Pharmacy
    Other

Market segment by players, this report covers
    Takeda
    CSL
    Grifols
    Octapharma
    Kedrion
    LFB Group
    Biotest
    BPL
    RAAS
    CBPO
    Hualan Bio
    Tiantan Bio
    Shuanglin Bio
    Boya Bio
    Yuanda Shuyang
    Weiguang Bio
    Nanyue Bio
    KM Biologics

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Plasma-derived Therapies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Plasma-derived Therapies, with revenue, gross margin, and global market share of Plasma-derived Therapies from 2019 to 2024.
Chapter 3, the Plasma-derived Therapies competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Plasma-derived Therapies market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Plasma-derived Therapies.
Chapter 13, to describe Plasma-derived Therapies research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Plasma-derived Therapies
    1.2 Classification of Plasma-derived Therapies by Type
        1.2.1 Overview: Global Plasma-derived Therapies Market Size by Type: 2024 Versus 2030
        1.2.2 Global Plasma-derived Therapies Revenue Market Share by Type in 2030
        1.2.3 Immune Globulin
        1.2.4 Coagulation Factor
        1.2.5 Albumin
        1.2.6 Other
    1.3 Global Plasma-derived Therapies Market by Application
        1.3.1 Overview: Global Plasma-derived Therapies Market Size by Application: 2024 Versus 2030
        1.3.2 Hospital
        1.3.3 Retail Pharmacy
        1.3.4 Other
    1.4 Global Plasma-derived Therapies Market Size & Forecast
    1.5 Market Drivers, Restraints and Trends
        1.5.1 Plasma-derived Therapies Market Drivers
        1.5.2 Plasma-derived Therapies Market Restraints
        1.5.3 Plasma-derived Therapies Trends Analysis

2 Company Profiles
    2.1 Takeda
        2.1.1 Takeda Details
        2.1.2 Takeda Major Business
        2.1.3 Takeda Plasma-derived Therapies Product and Solutions
        2.1.4 Takeda Recent Developments and Future Plans
    2.2 CSL
        2.2.1 CSL Details
        2.2.2 CSL Major Business
        2.2.3 CSL Plasma-derived Therapies Product and Solutions
        2.2.4 CSL Recent Developments and Future Plans
    2.3 Grifols
        2.3.1 Grifols Details
        2.3.2 Grifols Major Business
        2.3.3 Grifols Plasma-derived Therapies Product and Solutions
        2.3.4 Grifols Recent Developments and Future Plans
    2.4 Octapharma
        2.4.1 Octapharma Details
        2.4.2 Octapharma Major Business
        2.4.3 Octapharma Plasma-derived Therapies Product and Solutions
        2.4.4 Octapharma Recent Developments and Future Plans
    2.5 Kedrion
        2.5.1 Kedrion Details
        2.5.2 Kedrion Major Business
        2.5.3 Kedrion Plasma-derived Therapies Product and Solutions
        2.5.4 Kedrion Recent Developments and Future Plans
    2.6 LFB Group
        2.6.1 LFB Group Details
        2.6.2 LFB Group Major Business
        2.6.3 LFB Group Plasma-derived Therapies Product and Solutions
        2.6.4 LFB Group Recent Developments and Future Plans
    2.7 Biotest
        2.7.1 Biotest Details
        2.7.2 Biotest Major Business
        2.7.3 Biotest Plasma-derived Therapies Product and Solutions
        2.7.4 Biotest Recent Developments and Future Plans
    2.8 BPL
        2.8.1 BPL Details
        2.8.2 BPL Major Business
        2.8.3 BPL Plasma-derived Therapies Product and Solutions
        2.8.4 BPL Recent Developments and Future Plans
    2.9 RAAS
        2.9.1 RAAS Details
        2.9.2 RAAS Major Business
        2.9.3 RAAS Plasma-derived Therapies Product and Solutions
        2.9.4 RAAS Recent Developments and Future Plans
    2.10 CBPO
        2.10.1 CBPO Details
        2.10.2 CBPO Major Business
        2.10.3 CBPO Plasma-derived Therapies Product and Solutions
        2.10.4 CBPO Recent Developments and Future Plans
    2.11 Hualan Bio
        2.11.1 Hualan Bio Details
        2.11.2 Hualan Bio Major Business
        2.11.3 Hualan Bio Plasma-derived Therapies Product and Solutions
        2.11.4 Hualan Bio Recent Developments and Future Plans
    2.12 Tiantan Bio
        2.12.1 Tiantan Bio Details
        2.12.2 Tiantan Bio Major Business
        2.12.3 Tiantan Bio Plasma-derived Therapies Product and Solutions
        2.12.4 Tiantan Bio Recent Developments and Future Plans
    2.13 Shuanglin Bio
        2.13.1 Shuanglin Bio Details
        2.13.2 Shuanglin Bio Major Business
        2.13.3 Shuanglin Bio Plasma-derived Therapies Product and Solutions
        2.13.4 Shuanglin Bio Recent Developments and Future Plans
    2.14 Boya Bio
        2.14.1 Boya Bio Details
        2.14.2 Boya Bio Major Business
        2.14.3 Boya Bio Plasma-derived Therapies Product and Solutions
        2.14.4 Boya Bio Recent Developments and Future Plans
    2.15 Yuanda Shuyang
        2.15.1 Yuanda Shuyang Details
        2.15.2 Yuanda Shuyang Major Business
        2.15.3 Yuanda Shuyang Plasma-derived Therapies Product and Solutions
        2.15.4 Yuanda Shuyang Recent Developments and Future Plans
    2.16 Weiguang Bio
        2.16.1 Weiguang Bio Details
        2.16.2 Weiguang Bio Major Business
        2.16.3 Weiguang Bio Plasma-derived Therapies Product and Solutions
        2.16.4 Weiguang Bio Recent Developments and Future Plans
    2.17 Nanyue Bio
        2.17.1 Nanyue Bio Details
        2.17.2 Nanyue Bio Major Business
        2.17.3 Nanyue Bio Plasma-derived Therapies Product and Solutions
        2.17.4 Nanyue Bio Recent Developments and Future Plans
    2.18 KM Biologics
        2.18.1 KM Biologics Details
        2.18.2 KM Biologics Major Business
        2.18.3 KM Biologics Plasma-derived Therapies Product and Solutions
        2.18.4 KM Biologics Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Plasma-derived Therapies Revenue and Share by Players (2024 & 2030)
    3.2 Plasma-derived Therapies Players Head Office, Products and Services Provided
    3.3 Plasma-derived Therapies Mergers & Acquisitions
    3.4 Plasma-derived Therapies New Entrants and Expansion Plans

4 Global Plasma-derived Therapies Forecast by Region
    4.1 Global Plasma-derived Therapies Market Size by Region: 2024 VS 2030
    4.2 Global Plasma-derived Therapies Market Size by Region, (2024-2030)
    4.3 North America
        4.3.1 Key Companies of Plasma-derived Therapies in North America
        4.3.2 Current Situation and Forecast of Plasma-derived Therapies in North America
        4.3.3 North America Plasma-derived Therapies Market Size and Prospect (2024-2030)
    4.4 Europe
        4.4.1 Key Companies of Plasma-derived Therapies in Europe
        4.4.2 Current Situation and Forecast of Plasma-derived Therapies in Europe
        4.4.3 Europe Plasma-derived Therapies Market Size and Prospect (2024-2030)
    4.5 Asia-Pacific
        4.5.1 Key Companies of Plasma-derived Therapies in Asia-Pacific
        4.5.2 Current Situation and Forecast of Plasma-derived Therapies in Asia-Pacific
        4.5.3 Asia-Pacific Plasma-derived Therapies Market Size and Prospect (2024-2030)
        4.5.4 China
        4.5.5 Japan
        4.5.6 South Korea
    4.6 South America
        4.6.1 Key Companies of Plasma-derived Therapies in South America
        4.6.2 Current Situation and Forecast of Plasma-derived Therapies in South America
        4.6.3 South America Plasma-derived Therapies Market Size and Prospect (2024-2030)
    4.7 Middle East & Africa
        4.7.1 Key Companies of Plasma-derived Therapies in Middle East & Africa
        4.7.2 Current Situation and Forecast of Plasma-derived Therapies in Middle East & Africa
        4.7.3 Middle East & Africa Plasma-derived Therapies Market Size and Prospect (2024-2030)

5 Market Size Segment by Type
    5.1 Global Plasma-derived Therapies Market Forecast by Type (2024-2030)
    5.2 Global Plasma-derived Therapies Market Share Forecast by Type (2024-2030)

6 Market Size Segment by Application
    6.1 Global Plasma-derived Therapies Market Forecast by Application (2024-2030)
    6.2 Global Plasma-derived Therapies Market Share Forecast by Application (2024-2030)

7 Research Findings and Conclusion

8 Appendix
    8.1 Methodology
    8.2 Research Process and Data Source
    8.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Plasma-derived Therapies Revenue by Type, (USD Million) 2024 VS 2030
 Table 2. Global Plasma-derived Therapies Revenue by Application, (USD Million), 2024 VS 2030
 Table 3. Takeda Corporate Information, Head Office, and Major Competitors
 Table 4. Takeda Major Business
 Table 5. Takeda Plasma-derived Therapies Product and Solutions
 Table 6. CSL Corporate Information, Head Office, and Major Competitors
 Table 7. CSL Major Business
 Table 8. CSL Plasma-derived Therapies Product and Solutions
 Table 9. Grifols Corporate Information, Head Office, and Major Competitors
 Table 10. Grifols Major Business
 Table 11. Grifols Plasma-derived Therapies Product and Solutions
 Table 12. Octapharma Corporate Information, Head Office, and Major Competitors
 Table 13. Octapharma Major Business
 Table 14. Octapharma Plasma-derived Therapies Product and Solutions
 Table 15. Kedrion Corporate Information, Head Office, and Major Competitors
 Table 16. Kedrion Major Business
 Table 17. Kedrion Plasma-derived Therapies Product and Solutions
 Table 18. LFB Group Corporate Information, Head Office, and Major Competitors
 Table 19. LFB Group Major Business
 Table 20. LFB Group Plasma-derived Therapies Product and Solutions
 Table 21. Biotest Corporate Information, Head Office, and Major Competitors
 Table 22. Biotest Major Business
 Table 23. Biotest Plasma-derived Therapies Product and Solutions
 Table 24. BPL Corporate Information, Head Office, and Major Competitors
 Table 25. BPL Major Business
 Table 26. BPL Plasma-derived Therapies Product and Solutions
 Table 27. RAAS Corporate Information, Head Office, and Major Competitors
 Table 28. RAAS Major Business
 Table 29. RAAS Plasma-derived Therapies Product and Solutions
 Table 30. CBPO Corporate Information, Head Office, and Major Competitors
 Table 31. CBPO Major Business
 Table 32. CBPO Plasma-derived Therapies Product and Solutions
 Table 33. Hualan Bio Corporate Information, Head Office, and Major Competitors
 Table 34. Hualan Bio Major Business
 Table 35. Hualan Bio Plasma-derived Therapies Product and Solutions
 Table 36. Tiantan Bio Corporate Information, Head Office, and Major Competitors
 Table 37. Tiantan Bio Major Business
 Table 38. Tiantan Bio Plasma-derived Therapies Product and Solutions
 Table 39. Shuanglin Bio Corporate Information, Head Office, and Major Competitors
 Table 40. Shuanglin Bio Major Business
 Table 41. Shuanglin Bio Plasma-derived Therapies Product and Solutions
 Table 42. Boya Bio Corporate Information, Head Office, and Major Competitors
 Table 43. Boya Bio Major Business
 Table 44. Boya Bio Plasma-derived Therapies Product and Solutions
 Table 45. Yuanda Shuyang Corporate Information, Head Office, and Major Competitors
 Table 46. Yuanda Shuyang Major Business
 Table 47. Yuanda Shuyang Plasma-derived Therapies Product and Solutions
 Table 48. Weiguang Bio Corporate Information, Head Office, and Major Competitors
 Table 49. Weiguang Bio Major Business
 Table 50. Weiguang Bio Plasma-derived Therapies Product and Solutions
 Table 51. Nanyue Bio Corporate Information, Head Office, and Major Competitors
 Table 52. Nanyue Bio Major Business
 Table 53. Nanyue Bio Plasma-derived Therapies Product and Solutions
 Table 54. KM Biologics Corporate Information, Head Office, and Major Competitors
 Table 55. KM Biologics Major Business
 Table 56. KM Biologics Plasma-derived Therapies Product and Solutions
 Table 57. Global Plasma-derived Therapies Revenue (USD Million) by Players (2024 & 2030)
 Table 58. Global Plasma-derived Therapies Revenue Share by Players (2024 & 2030)
 Table 59. Plasma-derived Therapies Players Head Office, Products and Services Provided
 Table 60. Plasma-derived Therapies Mergers & Acquisitions in the Past Five Years
 Table 61. Plasma-derived Therapies New Entrants and Expansion Plans
 Table 62. Global Market Plasma-derived Therapies Revenue (USD Million) Comparison by Region (2024 VS 2030)
 Table 63. Global Plasma-derived Therapies Revenue Market Share by Region (2024-2030)
 Table 64. Key Companies of Plasma-derived Therapies in North America
 Table 65. Current Situation and Forecast of Plasma-derived Therapies in North America
 Table 66. Key Companies of Plasma-derived Therapies in Europe
 Table 67. Current Situation and Forecast of Plasma-derived Therapies in Europe
 Table 68. Key Companies of Plasma-derived Therapies in Asia-Pacific
 Table 69. Current Situation and Forecast of Plasma-derived Therapies in Asia-Pacific
 Table 70. Key Companies of Plasma-derived Therapies in China
 Table 71. Key Companies of Plasma-derived Therapies in Japan
 Table 72. Key Companies of Plasma-derived Therapies in South Korea
 Table 73. Key Companies of Plasma-derived Therapies in South America
 Table 74. Current Situation and Forecast of Plasma-derived Therapies in South America
 Table 75. Key Companies of Plasma-derived Therapies in Middle East & Africa
 Table 76. Current Situation and Forecast of Plasma-derived Therapies in Middle East & Africa
 Table 77. Global Plasma-derived Therapies Revenue Forecast by Type (2024-2030)
 Table 78. Global Plasma-derived Therapies Revenue Forecast by Application (2024-2030)


List of Figures
 Figure 1. Plasma-derived Therapies Picture
 Figure 2. Global Plasma-derived Therapies Revenue Market Share by Type in 2030
 Figure 3. Immune Globulin
 Figure 4. Coagulation Factor
 Figure 5. Albumin
 Figure 6. Other
 Figure 7. Plasma-derived Therapies Revenue Market Share by Application in 2030
 Figure 8. Hospital Picture
 Figure 9. Retail Pharmacy Picture
 Figure 10. Other Picture
 Figure 11. Global Plasma-derived Therapies Market Size, (USD Million): 2024 VS 2030
 Figure 12. Global Plasma-derived Therapies Revenue and Forecast (2024-2030) & (USD Million)
 Figure 13. Plasma-derived Therapies Market Drivers
 Figure 14. Plasma-derived Therapies Market Restraints
 Figure 15. Plasma-derived Therapies Market Trends
 Figure 16. Takeda Recent Developments and Future Plans
 Figure 17. CSL Recent Developments and Future Plans
 Figure 18. Grifols Recent Developments and Future Plans
 Figure 19. Octapharma Recent Developments and Future Plans
 Figure 20. Kedrion Recent Developments and Future Plans
 Figure 21. LFB Group Recent Developments and Future Plans
 Figure 22. Biotest Recent Developments and Future Plans
 Figure 23. BPL Recent Developments and Future Plans
 Figure 24. RAAS Recent Developments and Future Plans
 Figure 25. CBPO Recent Developments and Future Plans
 Figure 26. Hualan Bio Recent Developments and Future Plans
 Figure 27. Tiantan Bio Recent Developments and Future Plans
 Figure 28. Shuanglin Bio Recent Developments and Future Plans
 Figure 29. Boya Bio Recent Developments and Future Plans
 Figure 30. Yuanda Shuyang Recent Developments and Future Plans
 Figure 31. Weiguang Bio Recent Developments and Future Plans
 Figure 32. Nanyue Bio Recent Developments and Future Plans
 Figure 33. KM Biologics Recent Developments and Future Plans
 Figure 34. Global Plasma-derived Therapies Revenue Market Share by Region (2024-2030)
 Figure 35. Global Plasma-derived Therapies Revenue Market Share by Region in 2030
 Figure 36. North America Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2024-2030)
 Figure 37. Europe Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2024-2030)
 Figure 38. Asia-Pacific Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2024-2030)
 Figure 39. South America Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2024-2030)
 Figure 40. Middle East & Africa Plasma-derived Therapies Revenue (USD Million) and Growth Rate (2024-2030)
 Figure 41. Global Plasma-derived Therapies Market Share Forecast by Type (2024-2030)
 Figure 42. Global Plasma-derived Therapies Market Share Forecast by Application (2024-2030)
 Figure 43. Methodology
 Figure 44. Research Process and Data Source

Companies Mentioned

Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics